Pluristem Therapeutics Develops PLX-RAD Cells for Use in Hematology
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HAIFA, Israel, May 7, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that it has identified its first clinical indication in the hematology field for its Placental eXpanded (PLX) RAD cells for the enhancement of the engraftment of Hematopoietic Stem Cells (HSC) in patients experiencing a delay or failure of their bone marrow transplant (BMT). This follows Pluristem's completion of additional pre-clinical studies showing promising results for PLX-RAD for this indication.
Help employers find you! Check out all the jobs and post your resume.
HAIFA, Israel, May 7, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that it has identified its first clinical indication in the hematology field for its Placental eXpanded (PLX) RAD cells for the enhancement of the engraftment of Hematopoietic Stem Cells (HSC) in patients experiencing a delay or failure of their bone marrow transplant (BMT). This follows Pluristem's completion of additional pre-clinical studies showing promising results for PLX-RAD for this indication.
Help employers find you! Check out all the jobs and post your resume.